Diligence memo · auto-generated · as of July 2, 2026
Alumis Inc.
Alumis Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Alumis Inc. operates in Biotechnology, based in SOUTH SAN FRANCISCO.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Alumis Inc. has raised $240M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $129M on 2024-03-04.
Most recent recorded round closed around 2024-07-17.
Valuation (modeled)modeled
Provath models Alumis Inc. at approximately $433M (range $181M–$599M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.22× the median modeled value of Series D+ Biotechnology companies in 2022–2024 (75 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 14 months.
Last raise 23 mo ago; this sector typically re-raises about every 14 months.
Slightly overdue versus sector cadence.
The last round was 3.2× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 98% of Biotechnology peers (4293 compared).
Modeled value ranks above 81% of those peers.
Closest niche peers: Areteia Therapeutics, Inc., GIO World Health Ltd, Crinetics Pharmaceuticals, Inc., 2seventy bio, Inc., Gio World Health (Europe) Sa.
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.